Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other healthcare stocks. The healthcare industry remains a vital and resilient sector which is ...

Cambridge, Massachusetts-based Biogen Inc. (BIIB) discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. With a market cap of $23 bill ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen Pharmachem Industries Ltd share price was up by 1.57% from the previous closing price of ₹1.27. Who are peers of Biogen Pharmachem Industries Ltd? The peers of Biogen Pharmachem ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

Biogen Pharmachem Industries Limited is an India-based company, which is not engaged in any activity. The Company is looking for the right opportunity to make the Company operational. What is the ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.